mk 0663 has been researched along with cefdinir in 1 studies
Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (cefdinir) | Trials (cefdinir) | Recent Studies (post-2010) (cefdinir) |
---|---|---|---|---|---|
549 | 173 | 265 | 33 | 0 | 10 |
Protein | Taxonomy | mk 0663 (IC50) | cefdinir (IC50) |
---|---|---|---|
SUMO-1 | Homo sapiens (human) | 6.25 | |
low molecular weight phosphotyrosine protein phosphatase isoform c | Homo sapiens (human) | 19.6 | |
carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1 | Homo sapiens (human) | 4.48 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for mk 0663 and cefdinir
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |